Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II - Clinical Trial NCTNCT06392009
Business Opportunities for NCT06392009
Connect with principal investigators, study coordinators, and key decision makers for this PHASE1, PHASE2 trial studying investigational therapy for Tuberous Sclerosis, Seizures, Malformations of Cortical Development, Focal Cortical Dysplasia, Sclerosis, Behavioral Symptoms.
Clinical Trial Information
- Study Sponsor
- Sponsor information available
- Drug/Intervention
- Study intervention details available
- Therapeutic Area
- Tuberous Sclerosis, Seizures, Malformations of Cortical Development, Focal Cortical Dysplasia, Sclerosis, Behavioral Symptoms
- Study Phase
- PHASE1, PHASE2
- Study Status
- RECRUITING
- NCT Number
- NCTNCT06392009
Find Contact Information
Access exclusive contact details for:
- Principal investigators and sub-investigators
- Study coordinators and research staff
- Site directors and facility contacts
- Sponsor representatives and CRO partners
- Business development professionals
- Clinical operations managers
Clinical Trial Locations
This study has 20 locations across Australia, Belgium, Canada, Italy, Netherlands, Poland, Spain, United Kingdom.
Study Site
South Brisbane, Australia
Study Site
Antwerp, Belgium
Study Site
Leuven, Belgium
Study Site
Calgary, Canada
Study Site
Toronto, Canada
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships